AI Verdict
RPRX has stronger fundamentals based on our AI analysis.
RS vs RPRX Fundamental Comparison
| Metric | RS | RPRX |
|---|---|---|
| Revenue | $14.3B | $2.4B |
| Net Income | $739.4M | $770.9M |
| Net Margin | 5.2% | 32.4% |
| ROE | 10.3% | 7.9% |
| ROA | 7.1% | 3.9% |
| Current Ratio | 4.88x | 2.40x |
| Debt/Equity | 0.20x | 0.92x |
| EPS | $13.98 | $1.78 |
Green = Better metric | Red = Weaker metric
You Might Also Compare
RS vs RPRX: Frequently Asked Questions
Is RS or RPRX a better buy in 2026?
Based on dual AI fundamental analysis (Claude and ChatGPT), RPRX has stronger fundamentals. RS is rated HOLD (68% confidence) while RPRX is rated HOLD (75% confidence). This is not investment advice.
How does RS compare to RPRX fundamentally?
RELIANCE, INC. has ROE of 10.3% vs Royalty Pharma plc's 7.9%. Net margins are 5.2% vs 32.4% respectively.
Which stock pays higher dividends, RS or RPRX?
RS has a dividend yield of N/A or no dividend while RPRX has N/A or no dividend. Check individual stock pages for detailed dividend history and payout ratios.
Should I invest in RS or RPRX for long term?
For long-term investing, consider that RS has HOLD rating with 68% confidence, while RPRX has HOLD rating with 75% confidence. Higher confidence indicates more consistent fundamentals from SEC filings. This is not investment advice - always do your own research.
What do the AI models say about RS vs RPRX?
Our dual AI system (Claude by Anthropic and ChatGPT by OpenAI) analyzes SEC 10-K and 10-Q filings independently. For RS vs RPRX, the AI consensus favors RPRX based on fundamental metrics including revenue growth, profitability, ROE, and balance sheet strength.